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Salmonella enterica causes systemic diseases (typhoid and paratyphoid fever), nontyphoidal septicemia (NTS), and gastroenteri-
tis in humans and other animals worldwide. An important but underrecognized emerging infectious disease problem in sub-
Saharan Africa is NTS in children and immunocompromised adults. A current goal is to identify Salmonellamutants that are not
pathogenic in the absence of key components of the immune system such as might be found in immunocompromised hosts.
Such attenuated strains have the potential to be used as live vaccines. We have used transposon-directed insertion site sequenc-
ing (TraDIS) to screen mutants of Salmonella enterica serovar Typhimurium for their ability to infect and grow in the tissues of
wild-type and immunodeficient mice. This was to identify bacterial genes that might be deleted for the development of live atten-
uated vaccines that would be safer to use in situations and/or geographical areas where immunodeficiencies are prevalent. The
relative fitness of each of 9,356 transposonmutants, representing mutations in 3,139 different genes, was determined in gp91/
phoxmice. Mutations in certain genes led to reduced fitness in both wild-type andmutant mice. To validate these results, these
genes were mutated by allelic replacement, and resultant mutants were retested for fitness in the mice. A defined deletion mutant
of cysEwas attenuated in C57BL/6 wild-type mice and immunodeficient gp91/ phoxmice and was effective as a live vaccine in
wild-type mice.
Salmonella enterica causes systemic diseases (typhoid and para-typhoid fever), nontyphoidal septicemia, and gastroenteritis in
humans and other animals worldwide. Salmonella enterica serovar
Typhi and S. enterica serovar Paratyphi are restricted to humans
and cause typhoid and paratyphoid fever, respectively. These are
important febrile illnesses often seen in crowded and impover-
ished populations with inadequate sanitation that are exposed to
unsafe water and food and in travelers visiting countries where
these diseases are endemic (1). In 2010, typhoid and paratyphoid
fevers together were estimated to account for 190,200 deaths (2).
Mortality rates in untreated typhoid fever can be 10 to 15%. In
some cases patients recover but remain carriers of the bacteria for
many years. Invasive nontyphoidal salmonellae (iNTS) are esti-
mated to cause over 2.1 million illnesses and 416,000 deaths in
Africa annually despite antimicrobial treatment. Vaccine develop-
ment for iNTS disease is a high priority (3). iNTS disease is linked
with conditions which impair the immune system, such as a lack
of antibodies in young children and multiple comorbidities, such
as advanced HIV infection, malaria, hemolysis, sickle cell disease
(SCD), malnutrition, and cytokine pathway deficiencies (4, 5).
Current measures for controlling Salmonella infections are far
from ideal. The emergence of new multidrug-resistant strains has
reduced the usefulness of most antimicrobials (6). Prevention by
implementation of hygienemeasures alone is proving insufficient.
Currently licensed vaccines are far from optimal, and no effective
vaccine or delivery system effective against NTS is available.
Live attenuated S. enterica vaccines are more effective in many
different infection systems than nonliving ones due to their ability
to generate protective T-helper 1 type immunity in addition to
antibody responses (7). New live attenuated vaccines against Sal-
monella currently are being developed and tested (8). However,
concerns remain about the use of live vaccines in general when
these are targeted to areas where the diseases are endemic with a
high incidence of conditions that impair the immune system, and
there is reluctance to use live vaccines in animals bred for food
production due to fears of side effects subsequent to the unlikely,
but possible, spread to humans. Reversion to virulence would
pose a serious threat to individuals with an impaired immune
system who may inadvertently receive the live vaccine. Immuno-
suppression can be transient, latent, or undiagnosed, possibilities
that are likely to be more frequent in children or in adults from
countries where sophisticated diagnostic facilities are not always
available.
We and others have found that some live attenuated Salmo-
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nella vaccines, such as aromatic-dependent (aro) mutants, htrA
mutants, and aroA htrA double mutants, can cause lethal infec-
tions in immunodeficient mice such as those lacking in the pro-
duction of reactive oxygen species (ROS), interleukin-12 (IL-12),
or gamma interferon (IFN-) and in mice lacking T cells (9, 10).
Therefore, bacterial mutants of these genes could be dangerous if
used in patients with similar immune defects.We also have shown
that other vaccines, specifically Salmonella pathogenicity island-2
(SPI-2) mutants of S. enterica, similar to the ones currently being
tested in humans, regain virulence in ROS-deficient animals (11)
and could prove dangerous in individuals with reduced efficiency
of the oxygen-dependent antimicrobial mechanisms of phago-
cytes (e.g., chronic granulomatous disease [CGD] or malaria pa-
tients) (12, 13). These immunodeficienciesmay very well be latent
in the individual at the time of vaccination.
A current goal is to identify mutations that would allow the
generation of live attenuated salmonellae that would not signifi-
cantly regain virulence in the absence of key components of the
immune system. The feasibility of this approach is supported by
the evidence that some Salmonella mutants can retain this atten-
uation in situations of serious immunodeficiency in animal mod-
els of systemic infection. For example, SPI-2 mutants are attenu-
ated in gene-targeted mice lacking IFN-, despite these strains
being virulent in ROS-deficient animals (14).
Recent advances in high-throughput techniques to assess si-
multaneously the genotypes and relative fitness of individuals in
complex pools of bacterial transposon (Tn) mutants allow us to
utilize a genome-wide screen for genes necessary for bacterial fit-
ness in the face of particular immunological challenges. Trans-
poson-directed insertion site sequencing (TraDIS) is one such
technique. TraDIS exploits very-high-throughput Illumina se-
quencing to obtain sequence reads directly from the region of
DNA flanking each Tn insert in pools of mutants (15). This allows
the location of the transposons to be precisely determined in a
massively parallel manner. The number of reads obtained for each
Tn allows the relative abundance of each mutant to be assessed,
and a quantitative measure of fitness can be obtained by compar-
ing data obtained before and after a selection step.
In the current study, we have used a stringent mouse model of
immunodeficiency to perform a genome-wide screenwith the po-
tential to identify genes that can disable reversion to virulence in
immunodeficient hosts and that therefore could be included in
new generations of live vaccines against invasive salmonelloses.
MATERIALS AND METHODS
Bacterial strains, media, and growth conditions. All wild-type (WT)
strains, defined mutants, and plasmids are summarized in Table 1. The
preparation of electrocompetent Escherichia coli and S. Typhimurium
cells and transformations was performed as previously described (21).
Bacteria were grown on Luria-Bertani (LB) medium. Media were supple-
mented with the appropriate antibiotic for selection (ampicillin, 100 g/
ml; kanamycin, 50 g/ml; chloramphenicol, 10 g/ml; tetracycline, 12.5
g/ml).
RecombinantDNA techniques. Standardmethodswere used formo-
lecular cloning (22). Chromosomal and plasmid DNA purification and
routine DNAmodifications, including restriction endonuclease digestion
of DNA, modifications of DNA, and ligations, were carried out using
commercial kits and supplies according to the manufacturers’ instruc-
tions (Qiagen, Thermo Fisher Scientific, and New England BioLabs).
DNA concentration and purity were measured using a NanoDrop ND-
1000 spectrophotometer. PCR primers (see Table S1 in the supplemental
material) were designed using Primer3 (http://frodo.wi.mit.edu/) and
purchased from Sigma (Sigma-Genosys, United Kingdom). PCRs were
performed in 25-l reaction volumes in 0.2 ml Eppendorf tubes in a
PerkinElmer Gene Amp 2400 thermal cycler. Reaction mixtures con-
tained 200 M deoxynucleoside triphosphates (dNTPs), 2 mM Mg2,
0.01 volume of Proof Start DNA polymerase (2.5 U l1; Qiagen), 0.1
volume of polymerase buffer (10), 1 M forward and reverse primers,
and template DNA (50 ng plasmid DNA or 100 ng chromosomal
DNA). Thermal cycler conditions were 94°C for 10min and then 35 cycles
of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min, followed by a final
extension at 72°C for 10 min.
Generation of defined mutants of S. Typhimurium. Mutants were
generated using a modification of the ET cloning procedure (23, 24) as
previously described (20). PCR was used to amplify the chloramphenicol
resistance cassette from pACYC184 (18), the kanamycin resistance cas-
sette from pACYC177 (18), or the tetracycline resistance cassette from
pBR322 (19) with 5= and 3= 60-bp homology arms complementary to the
flanking regions of the gene to be deleted. Approximately 1 g of linear
PCR product was used for integration into the chromosome using amod-
ification of the Lambda Red method (25), as previously detailed (26).
Transformants were selected by plating onto medium containing chlor-
amphenicol, kanamycin, or tetracycline as appropriate. Screening for the
loss of the pBADred helper plasmid was as previously described (27),
using MAST ID Intralactam circles (MAST Diagnostics, Bootle Mersey-
side, United Kingdom) to screen for the absence of beta-lactamase in
bacterial colonies. (Further details of the construction of mutants are
provided in the supplemental material).
Mouse infections. All animals were handled in strict accordance with
good animal practice as defined by the relevant international (Directive of
the European Parliament and of the Council on the Protection of Animals
Used for Scientific Purposes, Brussels 543/5) and local (Department of
Veterinary Medicine, University of Cambridge) animal welfare guide-
lines. All animal work was approved by the ethical review committee of
the University of Cambridge and was licensed by the United Kingdom
Government Home Office under the Animals (Scientific Procedures) Act
1986. Sex- and aged-matched 9- to 12-week-old C57BL/6 wild-type mice
(Harlan Olac Ltd.) and gp91/ phox mice (bred at the Wellcome Trust
Sanger Institute) were infected by intravenous (i.v.) injection of bacterial
suspensions in a volume of 0.2ml. Statically grown cultures of wild-type S.
TyphimuriumSL1344 and definedmutants were grownovernight at 37°C
from single colonies in 10 ml LB broth and then diluted in phosphate-
buffered saline (PBS) to the appropriate concentration for inoculation.
Bacterial cultures for the pools of Tn5 andMuTnmutants (TraDIS pools)
were grown as described previously (14). Inocula were enumerated by
plating dilutions onto LB agar plates. Mice were killed by cervical disloca-
tion, and the livers and spleens were aseptically removed and homoge-
nized in sterile water using a Colworth Stomacher 80. The resulting ho-
mogenate was diluted in a 10-fold series in PBS, and LB agar pour plates
were used to enumerate viable bacteria.
TraDIS analysis of S. Typhimuriummutant pools. The Illumina se-
quence reads from the input (bacteria inoculated into mice) and output
(bacteria recovered from infected livers and spleens) pools (ENA no.
ERA201074) were generated using single-end short-read sequencing with
Tn-specific primers and by massively parallel sequencing of Tn-flanking
regions in the input and output mutant pools. Genomic DNA was pre-
pared and 2 g fragmented by Covaris to an average size of 300 bp.
Following end repair and A tailing, a modified Illumina adapter, synthe-
sized and annealed by Integrated DNA Technologies (IDT) using oligo-
nucleotides SplA5_top and SplA5_bottom (see Table S1 in the supple-
mental material), was ligated to the fragments for 40 min at 20°C. Ligated
fragments were cleaned using Ampure XP beads (Beckman Coulter) with
a bead-to-sample ratio of 0.8 to 1. PCR enrichment of fragments contain-
ing the Tn was performed using a primer homologous to each end of
the Tn (Mu_AG_5=PCR, Mu_AG_3=PCR, Tn5_AG_5=PCR, or
Tn5_AG_3=PCR; see Table S1) in conjunction with an adapter-specific
Grant et al.
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primer containing an index tag (SplAP5.x; see Table S1). PCR products
were cleaned using Ampure XP beads (Beckman Coulter), quantified by
quantitative PCR (qPCR), and then pooled. The resultant products were
sequenced on a HiSeq2500 (Illumina) using a specially modified recipe to
overcome difficulties generated by the monotemplate Tn sequence.
Briefly, a Tn-specific sequencing primer (Mu_AG_5=seq, Mu_AG_3=seq,
Tn5_AG_5=seq, or Tn5_AG_3=seq; see Table S1) anneals to the Tn 10
bases away from the genomic DNA junction. Sequencing takes place with
no imaging for the first 10 cycles followed by imaging for the next 40
cycles. This gives a 40-bp genomic DNA read. The template is denatured,
the same sequencing primer is reannealed, and 10 cycles of sequencing
takes place to give a 10-bp Tn read.
Sequence analysis. Illumina reads generated from the genomic DNA
of the input and output pools containing Tn5 andMu Tn insertions were
stripped of the 5= Tn tags using Cutadapt version 1.8.1 (28), and the
remainder of each sequence read was mapped to the S. Typhimurium
SL1344 chromosome and plasmid sequences (GenBank accession num-
bers FQ312003, HE654724, HE654725, and HE654726) using BWAmem
version 0.7.12-r1039 (29). The raw input and output read counts were
loaded into R, version 3.0.2. A step was performed to eliminate nonspe-
cific background reads by filtering out the insertions with a total read
count across all samples of 	100 reads. DESeq2 version 1.4.5 (30) was
used to compare the reads mapped to specific insertion positions in the
input pools and the corresponding insertion positions in the output
pools. Following normalization to account for differential sequence cov-
erage between samples, dispersions in the replicate samples were esti-
mated, and a negative binomial distribution model implemented in
DESeq2 was used to test the hypothesis that fitness score was equal to zero
under the assumption that a particular mutant was present at equivalent
levels of sequence coverage in the input and output pools. We obtained P
values for all mutants, and the P values then were adjusted for multiple
testing using the Benjamini and Hochberg false discovery rate (31).
A fitness score for each Tn mutant was calculated as a log2 transfor-
mation of the ratio of normalized output-input read counts. Hence, the
calculated fitness scores (log2-fold change) represent the difference in
abundance of each mutant in the output pool relative to the input. We
defined significantly attenuatedmutants as those with a negative log2-fold
change and an adjusted P value (Benjamini-Hochberg) of0.05.
For comparative purposes, the sequence data from our previous study
investigating the survival of the same Tn mutants in BALB/c mice (32)
TABLE 1 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype or descriptiona Source and/or reference
S. Typhimurium
SL1344 Virulent in mice with an i.v. LD50 of	20 CFU for innately susceptible mice 16
SL1344Mu Tn
library
Random Tn mutants; Knr 17
SL1344 Tn5 Tn
library
Random Tn mutants; Knr 17
SL1344 aroC 
aroC, Cmr This study
SL1344 aroC aroD
htrA

aroC, Cmr; 
aroD, Knr; 
htrA, Tcr This study
SL1344 aroC ssaV 
aroC, Cmr; 
ssaV, Knr This study
SL1344 cydC 
cydC, Cmr This study
SL1344 cydD 
cydD, Cmr This study
SL1344 cydC cydD 
cydC 
cydD, Cmr This study
SL1344 cysE 
cysE, Cmr This study
SL1344 dksA 
dksA, Cmr This study
SL1344 ftsK 
ftsK, Cmr This study
SL1344miaA 
miaA, Cmr This study
SL1344 nuoK 
nuoK, Cmr This study
SL1344 nuo operon 
nuo operon, Cmr This study
SL1344 ptsI 
ptsI, Cmr This study
SL1344 recD 
recD, Cmr This study
SL1344 secG 
secG, Cmr This study
SL1344 seqA 
seqA, Cmr This study
SL1344 sucA 
sucA, Cmr This study
SL1344 suc operon 
suc operon, Cmr This study
SL1334 thdF 
thdF, Cmr This study
SL1344 tol operon 
tol operon, Cmr This study
SL1344 tol pal
operon

tol pal operon, Cmr This study
SL1344 yqiC 
yqiC, Cmr This study
E. coli
DH5 Subcloning efficiency DH5 competent cells; F 80lacZ
M15 
(lacZYA-argF)
U169 recA1 endA1 hsdR17(rK
mK
) phoA supE44 thi-1 gyrA96 relA1 
Thermo Fisher Scientific
Plasmids
pACYC177 Apr, Knr New England Biolabs, 18
pACYC184 Cmr, Tcr New England Biolabs, 18
pBR322 Apr, Tcr New England Biolabs, 19
pBADRED Apr 20
a LD50, 50% lethal infectious dose.
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were analyzed using the same methods as those described above, and the
correspondingmutants in the twodata sets (i.e., thosewith readsmapping
to the same genomic locus in the same orientation) were identified.
RESULTS AND DISCUSSION
S. Typhimurium TraDIS infections in C57BL/6 wild-type and
gp91/ phox mice. Gp91 is one of the subunits of the NADPH
oxidase essential for ROS production by phagocytes. ROS defi-
ciency becomes apparent from the very early stages of an S. en-
terica infection, leading to a reduction in initial killing of the bac-
teria and accelerated growth in the first few days of infection.
Therefore, a short course of infection (48 h) was required to in-
vestigate the behavior of S. Typhimuriummutants in the gp91/
phoxmice.
We screened 21 pools of 480 Tnmutants of S. Typhimurium in
each pool, covering 10,000 Tn5 and Mu Tn mutants, at a dose
of 5  104 log10 CFU (the mean input dose in each of the 21
pools was 4.65  0.04 log10 CFU; errors are given as standard
deviations) in duplicate 8-week-old C57BL/6 wild-type (WT) or
gp91/ phox mice. The dose and pool size were dictated by the
need to allow the progression of the infection until the 48-h time
point without it reaching lethal bacterial numbers. We adminis-
tered pools of S. Typhimurium Tn mutants via the parenteral i.v.
route in order to relate our outputs to those of genes and mecha-
nisms of immunity involved in the control of the systemic phase of
an invasive infection. The control of growth at this systemic level
(i.e., restraint of bacterial growth and dissemination) is an abso-
lute requirement for survival in S. enterica typhoidal and septice-
mic infections in several target hosts (32).
Mice were killed at 48 h postinfection (p.i.) when the mean
bacterial load per liver was, on average, 2.90 log10 CFU greater in
the gp91/ phoxmice than in C57BL/6 WT mice (gp91/ phox
mice, 8.51 0.33 log10 CFU; C57BL/6WTmice, 5.62 0.20 log10
CFU), and themean bacterial load per spleenwas, on average, 2.71
log10CFUgreater in gp91
/ phoxmice than inC57BL/6WTmice
(gp91/ phox mice, 8.42  0.27 log10 CFU; C57BL/6 WT mice,
5.72 0.20 log10 CFU).
The input and output pool genomic DNA enriched for trans-
poson junctions was sequenced using the Illumina platform as
described in Materials and Methods. A total of 9,356 mutants
(4,975 Mu and 4,381 Tn5) were unambiguously mapped at the
level of the single nucleotide to the SL1344 genome (i.e.,94% of
the Tn mutants screened were mapped). The reason for the lower
number of mapped mutants than the number of mutants in the
original input pools could be due to mutants not surviving the
initial growth in the input pool and/or the presence of duplicate
mutants in the library. A total of 3,139 different genes were dis-
rupted by the 9,356 Tn insertions.
The sites of insertion of all transposons in the S. Typhimurium
TraDIS mutant libraries, the identities of the genes that are dis-
rupted, and the fitness scores of the mutants are listed in Table S2
in the supplemental material. The fitness scores of the mutants
obtained during infection of C57BL/6 mice showed a high pro-
portion of seemingly attenuated mutants (see Fig. S1a in the sup-
plemental material). Additionally, the output read counts from
the two replicate C57BL/6 mice did not show a good correspon-
dence (see Fig. S1b), and the fitness scores did not correlate well
with those obtained from BALB/c mice (see Fig. S1c) in our pre-
vious study (32) (Fig. 1). From these observations, we concluded
that the C57BL/6mice had exhibited stochastic loss ofmutants for
reasons unrelated to their genotype (i.e., random dropout). In
contrast, only a small proportion of mutants were attenuated in
the gp91/ phox mice, with good correspondence between the
replicates and with the data obtained from BALB/c mice (see Fig.
S2). The random dropout was not identified in the BALB/c mice,
probably because of the increased bacterial load used as the inoc-
ulum in this model (1  106 CFU in the BALB/c mice versus
5 104 CFU in the C57BL/6mice), or in the gp91/ phoxmice
due to the absence of bacterial killing in this model. Thus, the
attenuated mutants in the C57BL/6 data set are likely to include
false negatives due to the random dropout of mutants in this
model (i.e.,mutants that have been assigned as attenuated but that
could be colonization proficient). This prevented an in-depth
comparison of the different genes that contributed to fitness in the
wild-type C57BL/6 and immunocompromised mice. However,
the data from the screen in the gp91/ phoxmicewere robust and
provided us with solid foundations to select representative genes
from the attenuated mutant lists and test defined allelic replace-
ment mutants of these genes in wild-type and immunocompro-
mised mice.
Analysis of defined allelic replacement S. Typhimuriummu-
tants in C57BL/6 WT and gp91/ phox mice. An ideal live at-
tenuated vaccine would need to colonize but be attenuated in an
immunocompetent host and to remain attenuated under condi-
tions where the immune system may be impaired. Candidate
genes for the generation of such vaccines will be among those that
lead to attenuatedmutant phenotypes in spleens and livers of both
C57BL/6WT and gp91/ phoxmice.We selected 14 genes that fit
this pattern, cydC, cydD, cysE, dksA, ftsK, miaA, nuoK, ptsI, recD,
secG, seqA, sucA, thdF, and yqiC, and deleted them by allelic re-
placement in S. Typhimurium. We also generated a double mu-
tant knocking out both cydC and cydD, a mutant containing a
deletion of the entire sucoperon, amutant containing a deletion of
the entire nuo operon, a mutant containing a deletion of the tol
operon (since many different tolmutants were attenuated and tol
genes previously have been shown to have a role in virulence/
fitness in mice [33]), and a mutant containing a deletion of the tol
pal operon. All of these were tested individually for attenuation in
C57BL/6 WT mice compared to levels in the SL1344 wild type,
administered by i.v. injection, and at the input doses detailed in
Table 2. We also included in the experiment controls mutants
lacking aroC, aroC aroD htrA, and aroC ssaV, which have estab-
lished roles in virulence and have been or are being used as vaccine
candidates (34–36). Each gene, or genes, was inactivated sepa-
rately by Red recombinase-mediated integration of linear PCR
amplicons by homologous recombination. Mice were killed at 7
days p.i. or earlier if clinical signs became apparent (Table 2).
Definedmutants of cydC, cydD, cydC cydD, recD, seqA, and the suc
operons were not attenuated in the C57BL/6 mice, and mice had
to be killed at 3 days p.i., along with the mice infected with wild-
type SL1344. Mice infected with defined ftsK, nuoK, and nuo
operon mutants were killed on day 4 p.i., as the mice displayed
clinical signs.Mice infected with a dksAmutant were killed on day
5 p.i. Mice infected with sucA and thdFmutants displayed clinical
signs at 6 days p.i. and were killed, although interestingly viable
bacterial counts in the livers and spleens were not high enough to
be consistent with the observed signs of infection, indicating that
the clinical signs are due to focal infection at other body sites.Mice
infected with cysE,miaA, ptsI, secG, tol operon, tol pal operon, and
yqiCmutants, as well as the controls infectedwith aroC, aroC aroD
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htrA, and aroC ssaV mutants, did not display any visible clinical
signs on day 7 p.i.
Given their attenuation inWTmice, cysE,miaA, ptsI, secG, and
yqiC mutants, along with the tol operon and tol pal operon mu-
tants, were used to infect gp91/ phox mice. We also included
aroC, aroC aroD, and ssaVmutants as controls.Mice were killed at
7 days p.i. or earlier if clinical signs became apparent (Table 3).
Mice infected with defined ptsI, ssaV, tol operon, and tol pal
FIG 1 Relative fitness scores (log2-fold change) plotted against normalized mean read counts. Fitness scores represent the log2-fold change in the sequence read
counts of output pools compared with those of the input pools. Output pools were obtained from the livers of gp91/ phox, C57BL/6, and BALB/c mice (32).
Significantly attenuated mutants, represented as red closed circles, are a population of mutants showing negative fitness scores and an adjusted P value
(Benjamini-Hochberg) of0.05.Mutants with fitness scores whichwere not significantly different from zero are shown as black circles. Thewide range of fitness
scores exhibited in the C57B/L6 mice is indicative of large-scale stochastic loss (i.e., random dropout) of mutants during those infections.
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operon mutants were killed on day 3 p.i., when they displayed
clinical signs. Mice infected with aroC, miaA, and secG mutants
were killed on day 4 p.i. Mice infected with a yqiC mutant were
killed on day 5 p.i. when they displayed clinical signs. Mice in-
fected with an aroC aroD or cysEmutant were killed on day 7 p.i.,
which was the predefined endpoint of the experiment. The cysE
and the aroC aroD mutants had higher bacterial counts in the
organs of the gp91/ phoxmice than in the C57BL/6WTmice. In
order to determine how long the gp91/ phoxmice could survive
infection with a cysE mutant, we performed a small pilot study,
infecting gp91/ phox mice with 5.72 log10 CFU of the SL1344
cysE mutant and then allowing the infection to proceed until the
mice displayed clinical symptoms. The mice had to be killed on
day 8 p.i., when the bacterial loads in the livers were 8.33  0.11
log10 CFU and the bacterial loads in the spleens were 7.81 0.05
log10 CFU. We next proceeded to compare the cysEmutant to an
aroC mutant in gp91/ phox mice (Fig. 2). At three different
input doses, the time until the appearance of clinical signs was
consistently delayed for the cysEmutant compared to that for the
aroCmutant.
As a prerequisite to a vaccination study, we determined the
time it took for the SL1344 cysEmutant to be cleared from the liver
TABLE 2 CFU in the organs of C57BL/6 WT mice infected with defined mutants of S. Typhimurium, TraDIS fitness scores, and the number of
mutants in each gene identified by TraDIS
Mutation
Inoculum
(log10 CFU) Organ
Counts in organs
(mean log10 CFU SD) Day p.i. TraDIS fitness score
cydC 5.60 Liver 8.19 (0.05) 3 3.3; 1 mutant
Spleen 8.03 (0.19) 2.8; 1 mutant
cydD 5.51 Liver 8.40 (0.11) 3 2.6 (upper),3.8 (lower); 3 mutants
Spleen 8.34 (0.12) 2.2 (upper),4.1 (lower); 3 mutants
cydC cydD 5.54 Liver 7.86 (0.28) 3 Not available
Spleen 8.00 (0.36) Not available
recD 5.70 Liver 8.47 (0.21) 3 4.9; 1 mutant
Spleen 8.07 (0.33) 3.2; 1 mutant
seqA 5.65 Liver 8.37 (0.09) 3 5.5; 1 mutant
Spleen 8.18 (0.07) 2.6; 1 mutant
suc operon 5.49 Liver 8.54 (0.01) 3 0.8 (upper),5.3 (lower); 4 mutants
Spleen 8.30 (0.04) 0.3 (upper),5.9 (lower); 4 mutants
SL1344 WT 3.28 Liver 5.47 (0.23) 3 Not available
Spleen 5.72 (0.16) Not available
ftsK 5.64 Liver 7.61 (0.21) 4 5.1; 1 mutant
Spleen 7.14 (0.22) 5.8; 1 mutant
nuoK 5.72 Liver 8.35 (0.33) 4 3.3 (upper),4.8 (lower); 2 mutants
Spleen 8.05 (0.06) 2.8 (upper),4.4 (lower); 2 mutants
nuo operon 5.73 Liver 8.35 (0.13) 4 0.3 (upper),4.4 (lower); 18 mutants
Spleen 8.10 (0.13) 1.7 (upper),6.6 (lower); 18 mutants
dksA 5.69 Liver 8.49 5 4.3; 1 mutant
Spleen 8.19 3.9; 1 mutant
sucA 5.71 Liver 5.99 (0.61) 6 5.4; 1 mutant
Spleen 6.71 (0.27) 5.9; 1 mutant
thdF 5.48 Liver 7.00 (1.98) 6 2.4 (upper),6.4 (lower); 2 mutants
Spleen 7.07 (1.57) 2.7 (upper),3.8 (lower); 2 mutants
aroC 5.32 Liver 5.30 (0.16) 7 4.0 (upper),4.2 (lower); 2 mutants
Spleen 5.89 (0.08) 3.2 (upper),3.9 (lower); 2 mutants
aroC aroD htrA 5.36 Liver 2.63 (0.08) 7 Not available
Spleen 3.46 (0.11) Not available
aroC ssaV 5.51 Liver 5.02 (0.18) 7 Not available
Spleen 5.64 (0.05) Not available
cysE 5.51 Liver 5.61 (0.11) 7 2.8; 1 mutant
Spleen 5.88 (0.15) 4.1; 1 mutant
miaA 5.53 Liver 4.53 (0.19) 7 5.0 (upper),7.2 (lower); 4 mutants
Spleen 4.68 (0.10) 4.4 (upper),5.8 (lower); 4 mutants
ptsI 5.57 Liver 6.99 (0.53) 7 1.5; 1 mutant
Spleen 6.95 (0.44) 2.1; 1 mutant
secG 5.65 Liver 6.67 (1.09) 7 5.2; 1 mutant
Spleen 5.95 (0.48) 5.7; 1 mutant
tol operon 5.74 Liver 3.27 (0.20) 7 4.4 (upper),5.4 (lower); 6 mutants
Spleen 3.93 (0.09) 4.5 (upper),9.0 (lower); 6 mutants
tol pal operon 5.54 Liver 3.42 (0.10) 7 Not available
Spleen 4.07 (0.16) Not available
yqiC 5.65 Liver 6.53 (0.72) 7 6.0; 1 mutant
Spleen 6.39 (0.21) 5.9; 1 mutant
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and spleen ofWTC57BL/6mice (Fig. 3).We found that by day 84
p.i., mice infected i.v. had cleared all of the SL1344 cysE mutant
from the liver and spleen, while in the orally infected group it took
until day 91 p.i. for the organs to be clear of the SL1344 cysE
mutant.
We next vaccinated WT C57BL/6 mice, either i.v. or orally,
with the SL1344 cysE mutant and then challenged the mice, 91
days postimmunization, orally with virulent SL1344 and moni-
tored the bacterial counts in the livers and spleens at various times
postinfection (Fig. 4). The majority of the vaccinated mice were
protected from challengewith the virulent SL1344.However, dur-
ing the challenge experiment it was necessary to kill six mice (five
from the orally immunized group and one from the i.v. immu-
nized group) because they were displaying signs of infection.
Thus, 97% of the SL1344 cysE mutant i.v. vaccinated C57BL/6
mice and 86% of the SL1344 cysE mutant orally vaccinated
C57BL/6 mice were protected against challenge with virulent
SL1344.
Conclusion.Here, we have presented a report of the fitness of
random Tn mutants of S. Typhimurium in vivo and described
attenuated mutants based on the TraDIS analysis of pools of Tn
mutants screened in C57BL/6 WT and gp91/ phox mice. Our
study provides proof-of-principle data on the feasibility of using
TraDIS analysis in combination with infections of gene-targeted
animals to allow the identification of bacterial mutants as live
vaccine candidates that would be safe in situations where the im-
mune system is impaired.
We show that through TraDIS analysis it is possible to identify
novel mutations in S. Typhimurium genes that still allow coloni-
zation in WT mice but importantly also reduce bacterial growth
rate in vivo in severely immunodeficient gp91/ phox mice. It is
worth noting that the variance of definedmutants from their Tra-
DIS fitness scores (Tables 2 and 3) likely is due to differences in
TABLE 3 CFU in the organs of gp91/ phoxmice infected with defined mutants of S. Typhimurium, TraDIS fitness scores, and the number of
mutants in each gene identified by TraDIS
Mutation
Inoculum
(log10 CFU) Organ
Counts in organs
(mean log10 CFU SD) Day p.i. TraDIS fitness score
ptsI 5.60 Liver 7 3 4.5; 1 mutant
Spleen 8.40 (0.06) 4.0; 1 mutant
ssaV 5.69 Liver 9.01 (0.10) 3 2.9 (upper),5.3 (lower); 4 mutants
Spleen 8.63 (0.11) 3.1 (upper),5.6 (lower); 4 mutants
tol operon 5.48 Liver 8.30 (0.80) 3 5.8 (upper),7.6 (lower); 7 mutants
Spleen 8.00 (1.00) 5.8 (upper),6.8 (lower); 7 mutants
tol pal operon 5.45 Liver 8.28 (0.29) 3 Not available
Spleen 7.53 (0.44) Not available
aroC 5.56 Liver 7.83 (0.32) 4 5.6 (upper),6.0 (lower); 2 mutants
Spleen 7.59 (0.48) 5.3 (upper),6.5 (lower); 2 mutants
miaA 5.60 Liver 9.86 (0.04) 4 4.4 (upper),6.1 (lower); 4 mutants
Spleen 9.27 (0.32) 5.8 (upper),7.7 (lower); 4 mutants
secG 5.34 Liver 8.85 (0.38) 4 6.9; 1 mutant
Spleen 8.64 (0.14) 7.3; 1 mutant
yqiC 5.51 Liver 9.19 (0.21) 5 0.3; 1 mutant
Spleen 8.05 (0.13) 7.7; 1 mutant
aroC aroD 5.76 Liver 8.06 (0.14) 7 Not available
Spleen 7.75 (0.08) Not available
cysE 5.63 Liver 7.89 (0.07) 7 5.2; 1 mutant
Spleen 7.55 (0.22) 5.9; 1 mutant
FIG 2 Time to presentation of clinical signs in gp91/ phox mice infected
with various doses of the SL1344 cysE or SL1344 aroC mutant. gp91/ phox
mice were infected i.v. with 5.85 log10 CFU, 4.85 log10 CFU, or 3.85 log10 CFU
of either the SL1344 aroC (gray symbols) or SL1344 cysE (black symbols)
mutant, and the time to clinical signs was monitored.
FIG 3 WT C57BL/6 mice were infected i.v. (circles) or orally (triangles) with
5.80 log10 CFU or 8.68 log10 CFU, respectively, of the SL1344 cysEmutant, and
bacterial counts in the livers (L) and spleens (S) were monitored at various
times postinfection until the bacteria had cleared from the organs.
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competition dynamics for a given mutant relative to those of co-
screened mutant bacteria, as we previously demonstrated (32),
and the differences in time points at which the bacteria were enu-
merated p.i. between the TraDIS screen and the defined mutant
experiments. Thus, some of the attenuated mutants identified in
the screen are virulentwhen tested individually, while some others
retain the attenuation; therefore, the screen is useful but requires
further evaluation of mutations individually.
Through the TraDIS screens and validation of defined mu-
tants, we identified that the SL1344 cysE mutant was attenuated
for growth, was cleared fromWTC57BL/6mice, and had reduced
growth in gp91/ phoxmice, although these mice succumbed to
the infection 8 days p.i. The SL1344 cysE mutant offered protec-
tion when given i.v. or orally as a live vaccine to C57BL/6 WT
mice; however, a few of the vaccinated mice succumbed to the
challenge with the virulent SL1344, indicating that cysE does not
offer full protection to all vaccinated animals.
Our work did not identify a single-gene S. Typhimurium mu-
tant that would colonize WT animals at levels sufficient to be
predicted to be immunogenic and that also would be completely
unable to cause disease in the severely immunodeficient animals
used in this study. The attractive possibility that different combi-
nations of mutations could yield this ideal vaccine candidate re-
mains to be explored. However, even mutations that reduce
growth in immunocompromised hosts would be advantageous
and could be used to construct live strains in a way that would
crucially enable more time for medical intervention should an
immunocompromised vaccinee develop signs of infection. Fur-
thermore, the animal model that we used was of extreme immu-
nodeficiency, while it is likely that in the field one would encoun-
ter situations where macrophage function is only partially
impaired. Therefore, it remains to be established whether some of
themutants identified from this study would be safer inmodels of
partial immunodeficiency.
Extending the approach reported here to other gene-targeted
mouse strains has the potential in the future to generate a more
comprehensive picture of the functional interactions between the
bacterial and host genomes and to identify bacterial mutants as
live vaccine candidates that would be safe across a wide range of
immunodeficiencies.
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